A pathologist’s perspective on triple negative breast cancer

BulletArticle
Screenshot showing the title page of the Oncology-Pathology Perspectives in the management of advanced triple negative breast cancer patients webinar

Listen to perspectives from Professor Tan Puay Hoon, Senior Consultant Histopathologist and Chairman of the Division of Pathology at Singapore General Hospital, as she discusses triple negative breast cancer from a pathologist’s standpoint. In this recent webinar supported by the Singapore Society of Oncology, Prof Tan highlights the WHO guidelines for evaluating tumour infiltrating lymphocytes and explains why PD-L1 testing is crucial for identifying potentially immunotherapy responsive patients.

Prof Tan notes that PD-L1 immunohistochemistry (IHC) staining is not without limitations and challenges. To address this, she shares about their study on multiplex immunofluorescence, where multiple PD-L1 clones on the same tissue section yielded comparable results with traditional IHC. Although not yet widely implemented, it is a promising candidate for future use.

More on same topic

Recommended topics

SequencingRED 2020Rare Diseases
Next Read
Scroll to Top